New drug YSCH-01 with immunotherapy for recurrent brain cancer
Treatments studied
Part of Cancer, Infections clinical trials.
This early-stage trial tests a new drug called YSCH-01, alone or combined with an immunotherapy drug (atezolizumab), for glioblastoma that has come back after previous treatment. The study places a small tube in the brain to deliver the drug directly and monitors safety and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Expected to live at least 12 weeks
- Good overall health and ability to care for yourself (Karnofsky score ≥70)
- Glioblastoma (a type of brain cancer) that has returned after surgery, chemotherapy, and/or radiation
- One tumor visible on MRI that is 1–4 cm in size
- Healthy blood counts, liver, and kidney function to safely have a biopsy and brain tube placed
- Recovered from side effects of previous cancer treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the immunotherapy drug atezolizumab can help people with glioblastoma that has come back after initial treatment. You will need to have a biopsy before starting the drug to confirm the tumor has returned.
This trial tests a new drug called BL-B01D1 for people whose glioblastoma has come back after standard treatment. The goal is to see if the drug can help control the tumor.
This trial tests a combination of low-dose radiation, an immunotherapy drug (sintilimab), and chemotherapy (temozolomide) for people with glioblastoma that has come back. The goal is to see if this approach can help control the tumor and improve survival.
This trial tests a new drug (KH617) for people with glioblastoma that has returned after initial treatment. It may offer a new option for those whose tumor type is not helped by standard chemotherapy.
This trial tests an experimental oral drug called CT-179, which targets a protein involved in brain tumor growth. It may help people with glioblastoma, a type of brain cancer, when standard treatments have not worked or as part of initial treatment.
This trial is testing a new drug (JL15003) given directly into the brain tumor using a small device called an Ommaya reservoir. It is for people whose glioblastoma has come back despite standard treatments. You will need to have had a polio vaccine booster before starting.
Hear when a new Recurrent Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.